US: ATHXQ - Athersys Inc

Yield per half year: +900%
Dividend yield: 0.00%

Share chart Athersys Inc


About Athersys Inc

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

more details
The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.athersys.com
Цена ао 0.001
Change price per day: 0% (0.001)
Change price per week: 0% (0.001)
Change price per month: 0% (0.001)
Change price per 3 month: +900% (0.0001)
Change price per half year: +900% (0.0001)
Change price per year: -83.33% (0.006)
Change price per year to date: +900% (0.0001)

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -3.48 0
Yield Ebitda, % 0 0
Yield EPS, % 554.84 10
Total: 5.2

Head Job title Payment Year of birth
Ms. Z. Kasey Rosado Interim CFO & Director 1974 (51 year)
Senthil Ranganathan Ph.D. Vice President of Technical Operations
Mr. David Russ M.B.A. Vice President of Supply Chain, Finance & Administration
Dr. Manal Morsy M.B.A., M.D., PH.D. Executive VP & Head of Global Regulatory Affairs
Dr. Robert Mays Ph.D. Executive VP, Head of Regenerative Medicine & Neuroscience Programs
Mr. Rakesh Ramachandran MS Head of Information Technology & Communications and VP
Dr. Sarah Busch Ph.D. VP of Regenerative Medicine & Head of Business Development
Ms. Ellen Gurley Manager of Corporate Communications and Investor Relations

Address: United States, Cleveland, 3201 Carnegie Avenue - open in Google maps, open in Yandex maps
Website: https://www.athersys.com